New shot shows promise in lowering 'Bad' cholesterol in large trial

NCT ID NCT07295418

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 study tested a new injectable drug called SAL003 in 618 adults with high cholesterol or mixed dyslipidemia. Participants received either SAL003 or a placebo every 4 weeks for 12 weeks, then all received SAL003 for another 40 weeks. The main goal was to see if SAL003 lowers LDL ('bad') cholesterol more than placebo. The trial is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SAL003 (a PCSK9 inhibitor injection)
What this could lead to
If successful, SAL003 could offer a new injectable option to help lower 'bad' LDL cholesterol in people with high cholesterol, potentially reducing heart disease risk.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not prove superior to placebo or may have side effects. It is tested only in Chinese adults, so results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100083, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.